Edition:
United Kingdom

Second Sight Medical Products Inc (EYES.OQ)

EYES.OQ on NASDAQ Stock Exchange Capital Market

1.71USD
16 Feb 2018
Change (% chg)

$-0.05 (-2.84%)
Prev Close
$1.76
Open
$1.80
Day's High
$1.82
Day's Low
$1.70
Volume
86,280
Avg. Vol
124,450
52-wk High
$2.58
52-wk Low
$0.90

Select another date:

Fri, Feb 16 2018

BRIEF-Second Sight Announces Market Entry Into Singapore With First Implant Of Argus II Retinal Prosthesis System

* SECOND SIGHT ANNOUNCES MARKET ENTRY INTO SINGAPORE WITH FIRST IMPLANT OF ARGUS II RETINAL PROSTHESIS SYSTEM Source text for Eikon: Further company coverage:

BRIEF-SECOND SIGHT RECEIVES FDA EXPEDITED ACCESS PATHWAY DESIGNATION FOR ORION SYSTEM

* SECOND SIGHT RECEIVES FDA EXPEDITED ACCESS PATHWAY DESIGNATION FOR THE ORION CORTICAL VISUAL PROSTHESIS SYSTEM

BRIEF-Second Sight Medical Products reports Q3 loss per share $0.12

* Second Sight Medical Products Inc - qtrly adjusted loss per share $0.11 Source text for Eikon: Further company coverage:

BRIEF-Second Sight receives FDA approval to begin first Orion human clinical study

* Second Sight receives full FDA approval to begin first Orion human clinical study

BRIEF-Second Sight Medical Products files for mixed shelf of upto $100 mln‍​

* Second Sight Medical Products Inc files for mixed shelf of upto $100 million - sec filing‍​ Source text : http://bit.ly/2gXz4DE Further company coverage:

BRIEF-Second sight receives German approval to begin study to implant and evaluate Argus II in better-sighted retinitis pigmentosa patients

* Second Sight receives approval from Bundesinstitut Für Arzneimittel Und Medizinprodukte in Germany to begin study to implant and evaluate Argus II in better-sighted retinitis pigmentosa patients Source text for Eikon: Further company coverage:

BRIEF-Second Sight receives conditional FDA approval to begin first Orion human clinical study

* Second sight receives conditional FDA approval to begin first Orion human clinical study

Select another date: